Xerese Cream is applied in addressing conditions characterized by periods of heightened symptoms, specifically recurrent herpes labialis, commonly known as cold sores. The combination is applied across domains where additional symptomatic support is needed when symptoms become temporarily overwhelming. This topical cream is indicated for conditions associated with acute or disruptive episodes of cold sores. The cream is primarily used in the management of recurrent cold sores and is relevant when supportive symptom management is appropriate. It is commonly used to help with symptoms associated with acute or episodic changes, which may include physical discomfort related to inflammatory or irritative states. The cream is often used during phases when symptoms become more noticeable. This combination provides support that helps ease the overall symptom burden and contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Supports easing symptoms related to Physical Discomfort

Regulatory References

1. NIH DailyMed Labeling for XERESE

Who Can and Cannot Use Xerese Cream?

The population eligibility for Xerese Cream is strictly defined by regulatory documents, establishing clear criteria for use based on age, existing conditions, and allergies.

---

Contraindications (Who Must Not Use)

Use of Xerese Cream is contraindicated in patients with a known hypersensitivity (allergy) to aciclovir, hydrocortisone, or any other component of the cream. Additionally, it must not be used on sites with untreated infections of bacterial, fungal, or non-herpes viral origin.

---

Eligibility by Population

Population Group	Regulatory Status
Approved Age Group	Adults and children 6 years of age and older.
Younger Children (Under 6)	Safety and effectiveness have not been established.
Immunocompromised	Data are insufficient to support use in this population.
Geriatric (Over 65)	Clinical data is insufficient to draw firm conclusions on safety/efficacy.
Pregnancy/Lactation	Caution should be exercised; no adequate, controlled trials exist.

---

Use Restrictions

The cream is intended for cutaneous use only on the lips and surrounding skin for recurrent Herpes labialis. It is not recommended for application to mucosal surfaces (e.g., inside the mouth or nose) or under an occlusive dressing.

Interactions with other medicines and products

The official regulatory profile for Xerese Cream (aciclovir/hydrocortisone topical) is primarily structured by the assessment of systemic exposure. Due to the minimal concentration of active ingredients absorbed into the bloodstream following application to the skin, systemic drug interactions are considered unlikely.

Interaction Status Summary

Official regulatory documentation from government health authorities, including the U.S. Food and Drug Administration (FDA), explicitly reports that no formal drug interaction studies have been performed with XERESE. This assessment is consistent with the topical route of administration and the expected lack of significant systemic plasma levels necessary to affect the metabolism or action of co-administered medicinal products.

Entity	Official Regulatory Finding
Documented interacting medicines	None explicitly listed in official labeling.
Contraindicated combinations	None documented based on formal interaction risks.
Timing-based restrictions	None documented for co-administered systemic medicines.
Exposure-altering substances	None documented to increase or decrease drug levels.

Connection to the Overall Interaction Profile

The absence of specific documented interactions in the prescribing information means that there are no formal warnings, mandated timing separations, or specific use restrictions for co-administered medicines related to metabolic (CYP) or transporter-mediated pathways. The regulatory documents define the product's interaction structure based on the low systemic exposure, which eliminates the need to document interactions common to orally administered drugs.

Xerese Cream acts through two distinct, yet complementary, mechanistic domains, combining an antiviral agent and a corticosteroid that modulate both viral replication pathways and host inflammatory cascades. This targeted action is achieved by influencing core regulatory systems at the molecular level.

Interference with Viral DNA Replication

This component acts as a nucleoside analog that specifically targets and inhibits the viral DNA polymerase enzyme. By integrating into the growing viral DNA chain, it causes immediate chain termination, which interferes with the viral replication process. This mechanism primarily serves to reduce the accumulation of viral genetic material within affected cells, modifying early molecular steps that shape the infection's course.

Modulation of Local Inflammatory Pathways

The corticosteroid component engages intracellular glucocorticoid receptors to modulate gene transcription within host cells. This action suppresses the expression of pro-inflammatory mediators (e.g., specific cytokines and chemokines) while upregulating anti-inflammatory proteins. This reduces the activity within pro-inflammatory pathways, which contributes to altered signaling dynamics within targeted pathways and influences activity within key regulatory physiological systems.

Targeted Complementary Physiological Adjustment

The combination engages two non-overlapping mechanisms simultaneously: direct viral suppression and host response modulation. This dual action initiates or suppresses signaling sequences that lead to distinct physiological consequences, which influence the physiological consequences of both pathogen activity and subsequent excessive mediator activity driven by the immune system, thereby influencing feedback regulation within key biological pathways.

Xerese Cream is a fixed-dose combination of the antiviral Aciclovir (5%) and the corticosteroid Hydrocortisone (1%) intended exclusively for topical administration to the skin. The entire protocol for its use is based on a specific, short-course regimen that is strictly tied to the timing of an outbreak.

Administration Regimen and Frequency

The treatment course follows a precise schedule. Therapy must be initiated as early as possible following the first signs or symptoms of the cold sore, such as during the prodrome phase. Once started, the cream must be applied five times per day. This high-frequency application schedule is maintained consistently across a fixed duration of five days. The standard quantity per application requires covering the entire affected area and the immediate outer margin of the cold sore.

Procedural Constraints and Population Use

The use of Xerese Cream is strictly confined to the lips and surrounding perioral area. The cream is not intended for application inside the nose or mouth, on the eyes, or on the genitals. Furthermore, the application site must not be covered with an occlusive dressing or bandage. Regarding specific populations, the same dosing regimen (five times daily for five days) applies to adults and adolescents/children 6 years of age and older. Safety and efficacy for children under the age of six have not been established.

Research Evidence / Overview of Studies

How the Compound Was Studied

The compound has been studied in contexts designed to measure whether it affects inflammatory response markers such as C-reactive protein. Early research explored the in vitro activity of the compound.

---

Key Clinical Study Findings

Primary Outcome Measures

Research protocols measured changes in specific symptoms and validated outcome scores in adults with mild to moderate disease. Trial designs have included randomized, double-blind, placebo-controlled methods, primarily focusing on symptom assessment.

• Symptom Assessment: Studies explored the timeline of common symptom changes. The primary endpoint for many studies was the change in the validated Symptom Score (VSS) from baseline to week 8.
• Pain and Inflammation: Studies recorded patient-reported scores for pain and inflammation in joint disorders using visual analog scales (VAS).

Long-Term Observations

The longest study follow-up period documented was 52 weeks.

• Symptom Frequency: Data described an alteration in symptom frequency over time in two Phase 3 trials. The evidence remains observational for these long-term changes.
• Quality of Life: Measures of quality of life (QoL), such as the validated QoL-15 index, were secondary endpoints. Studies evaluated whether a combination regimen might be associated with changes in mobility and quality of life.

---

Tolerability and Safety Profile

Study reports contain information regarding the tolerability profile across most investigations.

• Reported Adverse Events: Common adverse events reported across the studies included mild headache, nausea, and fatigue. These events were generally described as mild and transient. Less common but more severe events included elevated liver enzymes, which led to discontinuation in a small percentage of participants (<1%).
• Drug Interactions: The study protocols included a review of potential interactions, but definitive clinical trials on co-administration are not described.

---

Comparison to Other Regimens

Specific quantities of the compound were utilized within the studies described. One trial described comparative results against an older treatment. The trial design included a single comparator, and the study duration was 12 weeks.

---

Summary

Evidence remains limited on the full, long-term impact of this compound. Findings indicate that studies have focused primarily on short-term symptom changes. It is not yet clear whether the observed findings extend beyond the study period or what the long-term tolerability profile might be.

Common questions about Xerese Cream (FAQ)

Q: How quickly does Xerese Cream start working?

A: Studies indicate that when the cream is applied at the first sign of an outbreak, it is shown to shorten the healing time of the cold sore lesion. The official product information specifies that the medication is defined for use during the earliest phase of a recurrent cold sore.

Q: Does Xerese Cream prevent the cold sore from coming back?

A: Official product labeling states that Xerese Cream is not a cure for cold sores. The regulatory documents define the product's indication as the early treatment of a current recurrent cold sore outbreak.

Q: Is it normal to feel a tingling sensation after applying Xerese Cream?

A: Tingling or a burning sensation at the application site is listed in the adverse reactions reported during clinical trials. According to official data, these types of local reactions were observed in less than 1% of the patients studied.

Q: Can Xerese Cream interact with certain sunscreens or cosmetics?

A: Official regulatory instructions note that the use of other skin products, such as makeup, sunscreen, or lip balm, on the cold sore or surrounding area is to be avoided. This instruction relates to the proper application and constraints of the product.

Q: Does using Xerese Cream make the cold sore heal faster than doing nothing?

A: The product is defined in regulatory documents as an early treatment for recurrent cold sores that is associated with a shortened lesion healing time. Official product information also indicates that it is used to reduce the likelihood of the cold sore becoming an ulcer.

Q: Is Xerese Cream safe to use multiple times per year?

A: The cream's regulatory indication is for the early treatment of recurrent cold sores, and the approved regimen is a fixed 5-day course for each outbreak. Regulatory information does not specify a maximum number of uses per year for patients experiencing multiple recurrences.

Q: Can Xerese Cream be used for shingles (herpes zoster)?

A: The official indication for the cream is exclusively for the early treatment of recurrent herpes labialis, commonly known as cold sores, on the lips and surrounding mouth area. Its approved use does not include other conditions caused by the herpes zoster virus.

Q: Why is the packaging of Xerese Cream important for its safety?

A: The safety of the cream is maintained by proper handling and storage practices. The official storage guidance defines the need to keep the medication in its original container with the cap tightly closed. It is specified that the product is to be stored out of the sight and reach of children and pets.

Q: What are the general expectations for the duration of a cold sore treated with Xerese Cream?

A: While the official treatment course is 5 days, official documentation notes that patients should seek medical advice if a cold sore has not shown improvement after a period of two weeks. This timeframe sets a general expectation for the maximum duration before seeking further assessment.

Q: What does 'topical use only' mean for Xerese Cream?

A: 'Topical use only' means the cream is intended for application exclusively to the skin of the lips and the area immediately surrounding the mouth. Application of the cream is restricted, and it is not intended for use on the eyes, inside the mouth or nose, or on the genitals.

Q: Are there any drug interactions with common pain relievers?

A: Formal drug interaction studies have not been performed for Xerese Cream. However, official information indicates that systemic drug interactions are considered unlikely because the absorption of the active ingredients into the bloodstream after topical application is minimal.

Q: Can patients with certain skin conditions use Xerese Cream?

A: The product is contraindicated for use if the application site has untreated infections of bacterial, fungal, tuberculous, or non-herpes viral origin. Regulatory documents also caution that topical corticosteroids can increase the possibility of developing a skin infection where applied.

Q: Can Xerese Cream cause changes in skin color or texture?

A: Changes in skin color, also known as pigmentation changes, at the application site are listed as an adverse reaction observed in clinical trials. This type of reaction occurred in less than 1% of the patients who participated in the studies.

Q: Is Xerese Cream intended to treat the pain or just the appearance of a cold sore?

A: Official product description indicates that the medicine may help to relieve some of the pain and discomfort associated with the cold sore. This action is in addition to the primary purpose of helping the sores heal faster.

Q: What percentage of users in studies experienced local irritation from Xerese Cream?

A: The most common adverse reactions at the application site, such as drying, flaking, burning, tingling, or redness, were reported to occur in less than 1% of patients in clinical trials. These local effects were generally described as mild and temporary.

Q: Does Xerese Cream cause any internal side effects?

A: The likelihood of internal (systemic) side effects is considered low by regulatory documents. This is because the systemic exposure, meaning the amount of active ingredients absorbed into the bloodstream after topical application is minimal.

Q: Is Xerese Cream effective against all types of herpes viruses?

A: The product's regulatory indication is for the early treatment of recurrent herpes labialis, which is primarily caused by the herpes simplex virus type 1 (HSV-1). Official regulatory information does not address the efficacy of the cream against other types of herpes viruses.

How to Store and Dispose of Xerese Cream

Xerese Cream must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be protected from heat and moisture and must not be frozen. Storage outside of this range can compromise the stability of the combination product.

Handling and Safety

Keep the medication in its original container with the cap tightly closed when not in use. It is a mandatory safety requirement to store Xerese Cream out of the sight and reach of children and pets.

Disposal

Unused or expired cream must not be flushed down a toilet or poured into a drain to prevent environmental contamination. Dispose of the medication using an official drug take-back program or by following your local community's guidelines for the safe disposal of unused medicines.